ClinicalTrials.gg
Not yet recruitingNCT07945431Updated Nov 18, 2026

A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction

A Phase 2 interventional study of SRP-001 and Matching Placebo for SRP-001 in Acute Pain, Postoperative Pain and Pain, sponsored by South Rampart Pharma, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by South Rampart Pharma, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Planned enrollment
112th of 322
130 · median 86
Started
2026
with 13 others
Phase 2
56 of 353
8 open now
Primary completion
2027-02
later than 23 of 54 live
Registered
352nd of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 112th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 56 in phase 2, reaches primary completion later than 23 of the 54 other live ones, and was the 352nd registered.

Acute Pain

1,076 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.

Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).

03

Conditions studied

  • Acute Pain
  • Postoperative Pain
  • Pain
  • Dental Pain

Keywords

  • third molar extraction
  • dental impaction pain model
  • Acute pain
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female ≥ 18 and ≤ 50 years of age.
  • Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
  • Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
  • Has a body weight ≥ 45 kg and a (BMI) ≤ 35 kg/m2.
  • Female subjects of must have used an acceptable method of for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or (defined as no menses for 12 months without an alternative medical cause).
  • Free of abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
  • Able to provide written .
  • Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
  • History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or baseline laboratory abnormalities at Screening, defined as serum or AST > 1.5× the (ULN), or total > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
  • Complications from tooth extraction resulting in a "severe" surgical trauma rating.
  • Dental surgery within 60 days prior to Day 1.
  • Positive urine drug screen or alcohol breathalyzer test.
  • Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
  • Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
  • Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ‭≥ 4 weeks prior to Screening.‬‬‬‬‬‬‬‬‬‬‬
  • History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or for any condition within 6 months prior to dosing.
  • Difficulty swallowing oral medication.
  • drug exposure within 30 days or 5 half-lives.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    SRP-001

    SRP-001 Single Oral Suspension dose of 2,000 mg

    Drug: SRP-001

  • Placebo comparator
    Matching Placebo for SRP-001

    Matching Placebo for SRP-001 Oral Suspension

    Drug: Matching Placebo for SRP-001

Interventions

  • DrugSRP-001

    SRP-001 Oral Suspension

  • DrugMatching Placebo for SRP-001

    Matching Placebo for SRP-001 Oral Suspension

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)

    Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo.

    Time frame: 0 to 6 hours post-dose

Secondary outcomes

  1. Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)

    Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse)

    Time frame: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose

  2. Sum of pain relief (TOTPAR)

    Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose.

    Time frame: O to 2, 0 to 4, 0 to 6 and 0-8 hours.

  3. Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)

    Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

    Time frame: 0 to 8 hours post-dose

  4. Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)

    Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

    Time frame: 0 to 8 hours post-dose

  5. Time to first use of rescue medication

    Rescue medication time for SRP-001 compared with placebo

    Time frame: 0 - 6, 0-8, 0-24 hours post dose.

  6. Total rescue medication consumption

    Total rescue medication consumption for SRP-001 compared with placebo

    Time frame: 0 - 6, 0-8, 0-24 hours post dose.

  7. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication

    Time frame: Day 1 through Follow-up Visit (Day 8 ± 2 days)

  8. Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)

    Pain intensity difference (PID) Scale is -10 to 10 (higher is better)

    Time frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose

  9. Patient's global evaluation of study drug using a 5 point categorical scale

    Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent

    Time frame: Up to 6 hours post dose

  10. Number of participants with clinically significant abnormalities in laboratory abnormalities

    Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential)

    Time frame: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2

  11. Maximum Observed Plasma Concentration (CMax) of SRP-001

    CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  12. Time to maximum observed plasma concentration (Tmax) of SRP-001

    Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  13. Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001

    AUC0-12 of SRP-001 following a single 2,000mg oral dose.

    Time frame: Pre-dose through 12 hours post-dose

  14. Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001

    AUC0-t of SRP001 following a single 2,000mg oral dose

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  15. Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001

    AUC0-inf of SRP-001 following a single 2,000mg oral dose

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  16. Terminal elimination half life (t 1/2) of SRP-001

    t 1/2 of SRP-001 following a single 2,000mg oral dose

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  17. Apparent oral clearance (CL/F) of SRP-001

    CL/F of SRP-001 following a single 2,000mg oral dose

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  18. Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001

    Vz/F of SRP-001 following a single 2,000mg oral dose

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

  19. Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)

    Pain relief difference (PR)

    Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Other outcomes

  1. Time to first perceptible relief and time to confirmed perceptible pain relief

    TPPR and TCPR via stopwatch 1

    Time frame: 0-4.5 hours post dose

  2. Time to meaningful relief

    TMPR via Stopwatch 2

    Time frame: 0-4.5 hours post dose

  3. Time to complete pain relief

    TCOMPR, NPRS = 0

    Time frame: 0 to 8 hours post-dose

07

Study locations

1 site
  • CenExel JBR Clinical Research
    Salt Lake City, Utah 84107, United States
08

References and documents

Publications

  • Coderch C, Bazan HA, Bazan NG, Surjyadipta B, Alvarez-Builla J, de Pascual-Teresa B. Computational Insights into the Structural Basis for Reduced Hepatotoxicity of Novel Nonopioid Analgesics. ChemMedChem. 2025 Nov 18;20(22):e202500639. doi: 10.1002/cmdc.202500639. Epub 2025 Oct 21. PubMed 41118753 ↗
  • Olson AC, Afyusisye F, Egger J, Noyd D, Likonda B, Masalu N, Suneja G, Chao N, Zullig LL, Schroeder K. Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. Cancer Epidemiol. 2020 Aug;67:101772. doi: 10.1016/j.canep.2020.101772. Epub 2020 Jul 10. PubMed 32653779 ↗
  • Bazan HA, Giles BL, Bhattacharjee S, Edwards S, Bazan NG. A non-toxic analgesic elicits cell-specific genomic and epigenomic modulation by targeting the PAG brain region. Neurobiol Pain. 2025 Jul 20;18:100192. doi: 10.1016/j.ynpai.2025.100192. eCollection 2025 Jul-Dec. PubMed 40746432 ↗
  • Frelinger AL 3rd, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 May 15;14(1):11092. doi: 10.1038/s41598-024-61949-9. PubMed 38750089 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 2 months later.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 18, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945431
Lead sponsor
South Rampart Pharma, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Todd Bertoch, MD
Contact
t.bertoch@cenexel.com
928 830 7354
CenExel JBR Recruiting
Contact
Todd M Bertoch, MD
principal investigator · CenExel JBR Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion